Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY2018/19 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, Nov 5, 2019
Slide 1: Making it easier to be one of the girls
Making it easier_ to be one of the girls My stoma doesn’t define me. My friends know about it and they support me. I feel comfortable when we are hanging out. Coloplast Earnings Conference Call FY 2018/19 5 November 2019 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interven
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast delivered 8% organic growth for the tenth consecutive quarter and for 2018/19
Coloplast delivered 8% organic growth for the tenth consecutive quarter and 8% organic growth for 2018/19 2018/19 Highlights Revenue growth +9% • Full year organic growth of 8% (9% reported growth in DKK) driven Reported revenue (DKKm) by strong momentum across all business areas +8% Organic growth
Slide 4: Interventional Urology remains core to the Coloplast mission and value creation agenda
Interventional Urology remains core to the Coloplast mission and value creation agenda Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 18/19 growing 3-5% annually 11% Coloplast position ENDOUROLOGY MEN’S HEALTH WOMEN’S HEALTH SPECIALTY INTERVENTIONS of
Slide 5: Strong performance throughout 2018/19 across all business areas vs. market growth of 4-5%
Strong performance throughout 2018/19 across all business areas vs. market growth of 4-5% FY 18/19 revenue by business area FY 18/19 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm g
Slide 6: FY 2018/19 reported revenue grew 9% driven by solid organic growth of 8%
FY 2018/19 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • FY 2018/19 reported revenue increased by DKK 1,490m (DKKm) or 9% compared to FY 2017/18 158 17,939 • The majority of growth was driven by organic growth 1,277 55 contributing DKK 1,277m or 8% to r
Slide 7: EBIT before special items grew 9% in FY 2018/19
EBIT before special items grew 9% in FY 2018/19 Comments EBIT margin before special items development (%) • EBIT before special items increased 9% to DKK 5,556m with a reported margin before special items of 31% on par with last year • Gross margin of 68% in DKK compared to 67% last year -0.3 • Posi
Slide 8: Financial guidance for FY 2019/20
Financial guidance for FY 2019/20 Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • Stable growth trends across regions and business areas • Up to 1% negative price pressure from reforms in France, Holland Sales growth 7-8% 7-8% and Switzerland (organic) • Approx. half of 9% price cut in Ch
Slide 9: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /